글로벌 티미딜레이트 합성효소 억제제 약물 시장 - 2029년까지의 산업 동향 및 예측

시장 분석 및 통찰력 글로벌 티미딜레이트 합성효소 억제제 약물 시장

티미딜레이트 합성효소 억제제 약물 시장은 2022-2029년 예측 기간에 시장 성장을 이룰 것으로 예상됩니다. Data Bridge Market Research는 위에서 언급한 예측 기간에 시장이 6%의 CAGR로 성장할 것으로 분석합니다.

티미딜레이트 합성효소 억제제는 DNA 합성을 억제하여 종양 세포 발달을 예방하는 약물입니다. 암 치료제로 연구되고 있습니다. 티미딜레이트 합성효소(TS)는 엽산 의존 효소에서 2'-디옥시우리딘-5'-모노포스페이트를 2'-디옥시티미딘-5'-모노포스페이트로 환원적 메틸화를 촉진합니다. 이 시스템은 2'-디옥시티미딘-5'-트리포스페이트의 유일한 세포 내 신생 공급원이기 때문에 TS는 암 치료에서 중요한 표적입니다.

전 세계적으로 암 유병률의 증가는 티미딜레이트 합성효소 억제제 약물 시장 확대의 주요 원동력이 될 것입니다. 또한, 파이프라인 연구 수의 급증과 의료비 지출 증가는 티미딜레이트 합성효소 억제제 약물 시장을 확대할 요인입니다. 라이프스타일의 변화와 인식 제고를 포함한 다른 요인은 시장 성장률에 긍정적인 영향을 미칠 것입니다. 또한, 의료 기술의 발전, 정부 자금 지원 증가, 가처분 소득 수준의 증가는 티미딜레이트 합성효소 억제제 약물 시장의 성장률을 가속화할 요인입니다. 시장 성장률에 영향을 미치는 또 다른 중요한 요인은 노인 인구의 증가입니다. 또한, 글로벌 제약 회사의 집중도가 높아짐에 따라 시장 성장이 촉진될 것입니다.

Moreover, the rise in the research and development activities, ongoing clinical trials and emerging new markets will provide beneficial opportunities for the thymidylate synthase inhibitor drugs market in the forecast period of 2022-2029. Also, high unmet need of current treatment and developments in healthcare technology will escalate the growth rate of market in future.

However, high cost associated with drugs and lack of infrastructure in low-income countries will impede the growth rate of market. Additionally, adverse effects linked with chemotherapies will hinder the market growth. Also, the dearth of awareness regarding health in many under-developed countries will further challenge the market in the forecast period mentioned above.

This thymidylate synthase inhibitor drugs market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the thymidylate synthase inhibitor drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Thymidylate Synthase Inhibitor Drugs Market Scope and Market Size

The thymidylate synthase inhibitor drugs market is segmented on the basis of drug type, application, dosage form, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

• On the basis of drug type, the thymidylate synthase inhibitor drugs market is segmented into raltitrexed, pemetrexed, nolatrexed and others.
• On the basis of application, the thymidylate synthase inhibitor drugs market is segmented into non-small cell lung cancer (NSCLC), mesothelioma (MPM) and others.
• On the basis of dosage form, the thymidylate synthase inhibitor drugs market is segmented into injection, tablets and others.
• On the basis of route of administration, the thymidylate synthase inhibitor drugs market is segmented into oral, intravenous and others.
• On the basis of end-users, the thymidylate synthase inhibitor drugs market is segmented into clinic, hospital and others.

The thymidylate synthase inhibitor drugs market is also segmented on the basis of distribution channel into hospital pharmacy, retail pharmacy and online pharmacy.

Thymidylate Synthase Inhibitor Drugs Market Country Level Analysis

Thymidylate synthase inhibitor drugs market is analyzed and market size information is provided by the country, drug type, application, dosage form, route of administration, end-users and distribution channel as referenced above.

The countries covered in the thymidylate synthase inhibitor drugs market report are the U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa.

North America dominates the thymidylate synthase inhibitor drugs market due to the presence of major key players, high disposable income and well-developed healthcare infrastructure in this region. Asia-Pacific is expected to grow during the forecast period of 2022-2029 due to the increasing research and development activities, surging prevalence of chronic diseases and growing government support in this region.

The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Patient Epidemiology Analysis

Thymidylate synthase inhibitor drugs market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Competitive Landscape and Global Thymidylate Synthase Inhibitor Drugs Market Share Analysis

티미딜레이트 합성효소 억제제 약물 시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보에는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 글로벌 입지, 생산 현장 및 시설, 회사의 강점과 약점, 제품 출시, 임상 시험 파이프라인, 제품 승인, 특허, 제품 폭과 폭, 응용 분야 우세, 기술 수명선 곡선이 있습니다. 위에 제공된 데이터 포인트는 티미딜레이트 합성효소 억제제 약물 시장 조사와 관련된 회사의 초점에만 관련이 있습니다.

티미딜산 합성효소 억제제 약물 시장에서 활동하는 주요 기업으로는 Teva Pharmaceutical Industries Ltd., Fresenius Kabi India Pvt. Ltd., Cadila Pharmaceuticals, Eli Lilly and Company, Novartis AG, Amgen Inc., AstraZeneca, Sanofi, Bristol-Myers Squibb Company, Merck & Co., Inc., AbbVie Inc., F. Hoffmann-La Roche Ltd., Johnson & Johnson Private Limited, Mylan NV, Abbott, Pfizer Inc., Accord Healthcare, GlaxoSmithKline plc, Sun Pharmaceutical Industries Ltd., Bayer AG, Baxter 등이 있습니다.

SKU-67594